Cytokinetics (CYTK) Misses Q4 EPS by 24c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $80.01 --0%
EPS Growth %: -46.4%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -46.4%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.45), $0.24 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $1.96 million versus the consensus estimate of $7.45 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cytokinetics (CYTK) PT Raised to $118 at Mizuho
- EXL to acquire iMerit in deal valued at up to $310 million
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
